SL Insight Newsletter #9

The FOPH confirms on a new focus page that the US GENEROUS model uses Swiss drug prices as a reference. At the same time, the FOPH announces that it will further accelerate the inclusion in the specialty list and price setting; a revision of the ordinance with consultation is announced for the first quarter of 2026.

What exactly does the BAG say?

• BAG confirms: GENEROUS uses Swiss drug prices as a reference for US Medicaid pricing.
• According to the BAG, only original preparations in the Medicaid Drug Rebate Program are affected; according to the BAG, this represents less than 10% of US net sales.
• BAG announces further modernization of SL admission and price setting; revision of regulations with consultation in the first quarter of 2026.
• Authority emphasizes ongoing dialogue with industry; initial acceleration measures were already implemented in 2025.

What does this mean for companies?

For affected products, SL prices and Swiss net discounts may become direct anchors for US prices in the future. Any additional price reductions in Switzerland may therefore have repercussions on US business. It is now important to prepare input for the BAG consultation Q1/2026: sharpening the position on SL process acceleration and Switzerland's international reference price role.

Click here to go to the focus page.